Ottavia Amato
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy.
Journal: Breast (Edinburgh, Scotland)
Published: June 03, 2025
Rising Concern About the Carcinogenetic Role of Micro-Nanoplastics.
Journal: International journal of molecular sciences
Published: November 23, 2024
Circulating tumor DNA validity and potential uses in metastatic breast cancer.
Journal: NPJ breast cancer
Published: December 03, 2023
Epidemiology trends and progress in breast cancer survival: earlier diagnosis, new therapeutics.
Journal: Current opinion in oncology
Published: September 08, 2023
Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 11, 2023
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study.
Journal: Journal of clinical pathology
Published: February 23, 2023
Liquid biopsy accelerates precision medicine.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 25, 2023
Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation.
Journal: British journal of cancer
Published: December 02, 2022
PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer.
Journal: Cold Spring Harbor molecular case studies
Published: November 09, 2022
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation.
Journal: British journal of cancer
Published: June 07, 2022
Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer.
Journal: NPJ breast cancer
Published: November 25, 2021
Last Updated: 09/26/2026